Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer Publication Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…Danielle PillsburyMarch 4, 2026
ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Blog ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…CertaraMarch 3, 2026
Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development Conference Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development Danielle PillsburyMarch 2, 2026
Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes Blog Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…CertaraFebruary 27, 2026
Blog Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…CertaraFebruary 26, 2026
Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Webinar Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Danielle PillsburyFebruary 23, 2026
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success On-Demand Webinar Start right, finish strong: Antibody-drug conjugate (ADC) studies for success Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…CertaraFebruary 23, 2026
Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs) Webinar Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs) CertaraFebruary 23, 2026
Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs) Webinar Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs) CertaraFebruary 23, 2026
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development Blog FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…CertaraFebruary 18, 2026